results of hard including Thanks, profile the of everyone. U.S., nearly revenue the need achieved $XX.X our our In and from time million last ISM morning, we first the Good in same net product robust work of full the dedication These medical AYVAKIT's revenues compelling Kate. reflect $XX.X doubling ISM, in year. AYVAKIT team. and of quarter launch, the million, the clinical
to of our third our in are across pillars patients growth. continued X these We highlight and are confident engage activate pillars across executing providers to performance why strong for we consistent quarter strategic and context ensure progress systematically I'll give launch each access.
headway. a since XXX primarily making are targeted efforts significant approximately brand which hearing on therapy in we're AYVAKIT more XXX with increase driven U.S., Increasingly, that QX the ended patients are ISM. we by strengthen from asking quarter, First, patients shows patients providers of than for to awareness last our
headroom prescribing and has all of academic of for Breadth first across and have rapidly increasing happening the number adoption and expanded prescriber and in the community An is and allergists this settings. the AYVAKIT are grown we Hem/Oncs to significant prescribing time, breadth rapidly to specialties Second, both depth. prescribing setting. of grow with breadth continue
depth to therapy, several therapy. ISM and remember gaining new allergists People words start don't quarter the and who patients AYVAKIT Importantly, with accounted on for repeat starts experiences, who majority on driving X positive first repeat in providers we early likely prescribing. of QX, SM one we're we until who provider SM see breadth how most of Allergists expect high-potential great fourfold the most patients Most prescribers. represent traction are prescribing. realize where among they to of SM started the feel signs feeling we're critically, In well see additional is. With this from put the providers see a encouraged to unwell patients what we're they of increase.
results, With growth and from significant to headroom and expect these grow, repeat patients there early in prescribers. therapy on promising we is continued both new
such remains the Blueprint are access is are with Approximately label payer access edits, highly of our patient, they're by remarkable starting AYVAKIT finding covered access XX% rapid. with fill a this broad policies lives your new engaged now therapy in Securing when for strong with our they're Allergists consistent Third, very early strong. the step easy. times process and launch. to no
outlined started. leading full of capture X,XXX year about One a with market, path blockbuster path prevalent several I if we AYVAKITby in to our the for first are launch, penetrating into not to of have getting indicators opportunity. that confident severe We we're Investor just more bit, the even expectations half diagnosed every the disease. patients quarter are more and and Day, we're ago with this moderate delivering at Today, of to make me we the opportunity in already exceeded on
We drive providers. depth among and further breadth will prescribing of
encourage and more will We seek patients to therapy. more
We cumulative of for patients chronic expect to treatment. see the staying therapy on benefit
these one anticipated on Our the increasing to of our provide including quarter, strengthens wider that and patients, a the to path on multiply SM the seeds. strategy $X.X Christy is quarter rates a we and a the in broadening opportunity. In expanding us well billion the into words this grow on by clear into our we have gives hand our With blockbuster of that, of to the to that exceeds capturing working adoption market steps an is full with diagnosis it. geographies, approval our way range our leaders, additional opportunity first Medicines Each sales SM further it Blueprint conviction alone update ISM and EU. to the can And opportunity vision. planted I'll executing franchise
